June 21, 2022

Why Eli Lilly's Immunology Prospects Look Promising

Top pharmaceutical company Eli Lilly’s (NYSE: LLY) diabetes division achieved a key milestone with the approval of Mounjaro in May for type 2 diabetes. But not to be outdone, the company’s immunology division has responded with a string of good news.

This post was originally published on this site

Sign Up To Get FREE News, Tips and Offers!

X